Acute pulmonary edema (APE) is a life-threatening condition characterized by rapid fluid accumulation in the alveoli, most commonly from cardiogenic causes (elevated left ventricular filling pressures), resulting in severe dyspnea, hypoxemia, and respiratory failure. [1-2] A critical subset is sympathetic crashing acute pulmonary edema (SCAPE), defined by sudden severe pulmonary edema with hypertension, driven by elevated afterload and fluid maldistribution rather than true volume overload. [3] In-hospital mortality is approximately 10%, with one-year mortality of 30%. [1]
The Lynne Stevenson four-quadrant classification (warm/cold × wet/dry) provides a rapid bedside framework for categorizing patients and guiding initial therapy:
1. History
- Onset and timing: Sudden vs. gradual; paroxysmal nocturnal dyspnea (PND), orthopnea, and bendopnea are classic for cardiogenic etiology [2][5]
- Symptom characterization: Severity of dyspnea, cough (frothy/pink sputum), inability to lie flat, exercise intolerance
- Triggers: Dietary indiscretion (salt/fluid), medication nonadherence, new arrhythmia (especially atrial fibrillation), ACS symptoms (chest pain), recent infection, surgery, or blood transfusion [6]
- Baseline functional status: Prior NYHA class, usual weight, home oxygen use, prior intubations
- Important negatives: Absence of fever/chills (infection), pleuritic pain (PE), trauma, aspiration event, toxic ingestion — these help distinguish cardiogenic from noncardiogenic causes [2]
2. Alarm Features
- Hypotension (SBP <90 mmHg) or signs of cardiogenic shock: altered mentation, cool/mottled extremities, oliguria [5][7]
- Severe hypoxemia (SpO₂ <85%) refractory to supplemental O₂ [5]
- Respiratory failure with accessory muscle use, inability to speak in full sentences, impending respiratory arrest
- Acute coronary syndrome: chest pain with ischemic ECG changes — may require emergent catheterization [6]
- New hemodynamically significant arrhythmia (e.g., rapid AF, VT) [5]
- Anuria or rapidly worsening renal function
- Altered mental status or obtundation
3. Medications
First-line treatments
- Nitroglycerin — the cornerstone for hypertensive APE/SCAPE. High-dose bolus (400–2000 mcg IV) followed by infusion ≥100 mcg/min is safe and effective, reducing mechanical ventilation need and hospital stay. Contraindicated with recent PDE-5 inhibitor use, severe aortic stenosis, or SBP <90 mmHg [3][8-9]
- IV loop diuretics (furosemide 20–40 mg IV, or 1–2.5× home oral dose) — indicated when true volume overload is present (peripheral edema, weight gain, cardiomegaly). Should not be routinely given in SCAPE without evidence of fluid overload [3][10]
- NIPPV (BiPAP/CPAP) — reduces intubation rates and in-hospital mortality [1][11]
Second-line/refractory agents
- Clevidipine or nicardipine — for refractory hypertension despite nitroglycerin [3][12-13]
- Enalaprilat IV — option in resistant hypertension with normal renal function [3]
Medications to AVOID
- Beta-blockers — contraindicated in acute pulmonary edema (negative inotropy worsens cardiac output) [12]
- Opioids (morphine) — caution recommended; associated with increased intubation and ICU admission in SCAPE [3]
- NSAIDs — promote sodium retention and can precipitate HF decompensation [6]
- Verapamil/diltiazem — negative inotropic effect [6]
4. Diet
- Acute setting: NPO or clear liquids until respiratory status stabilizes
- Sodium restriction: <2 g/day is standard for HF patients to prevent recurrence
- Fluid restriction: Typically 1.5–2 L/day in patients with hyponatremia or refractory congestion
- Long-term: Counsel on daily weight monitoring (report gain >2 lbs/day or >5 lbs/week)
5. Review of Systems
- Cardiovascular: Chest pain, palpitations, syncope/presyncope, lower extremity swelling
- Respiratory: Cough (productive vs. dry), hemoptysis, wheezing, pleuritic pain
- GI: Abdominal distension, early satiety, RUQ pain (hepatic congestion), nausea
- Neurologic: Altered mentation, confusion (low output state)
- Renal: Decreased urine output, foamy urine
- Constitutional: Fever (infection as trigger), weight gain (fluid retention), fatigue
6. Collateral History and Family History
- Collateral: Medication adherence, recent dietary changes, substance use (cocaine, methamphetamine — potent causes of hypertensive APE), alcohol use (alcoholic cardiomyopathy)
- Prior HF history: Baseline EF, prior hospitalizations, home medications, usual weight, prior echo findings
- Family history: Cardiomyopathy, sudden cardiac death, premature coronary artery disease, familial hypertrophic cardiomyopathy
7. Risk Factors
- Coronary artery disease / prior MI
- Chronic hypertension (most common trigger for SCAPE) [3][8]
- Valvular heart disease (aortic stenosis, mitral regurgitation)
- Chronic kidney disease / ESRD (volume overload, inability to excrete sodium) — 36% of SCAPE patients in one series had ESRD [8]
- Atrial fibrillation and other arrhythmias [6]
- Diabetes mellitus, obesity
- Medication nonadherence (diuretics, antihypertensives)
- Dietary nonadherence (high-sodium meals)
- Substance use: Cocaine, methamphetamine, excessive alcohol
8. Differential Diagnosis
- Acute coronary syndrome — may present with or cause APE; obtain ECG and troponin [2]
- Pulmonary embolism — can mimic APE; D-dimer and SPAP on echo are highly discriminating [14]
- Pneumonia / sepsis — noncardiogenic pulmonary edema; fever, productive cough, leukocytosis [2]
- ARDS (noncardiogenic pulmonary edema) — associated with sepsis, aspiration, trauma, pancreatitis [15]
- Acute exacerbation of COPD/asthma — wheezing predominates; may coexist ("cardiac asthma")
- Tension pneumothorax — unilateral absent breath sounds, tracheal deviation
- Cardiac tamponade — Beck's triad, pulsus paradoxus
- Severe aortic or mitral valve pathology (acute MR from papillary muscle rupture, acute AR from endocarditis)
The following algorithm from Ware & Matthay provides a stepwise approach to differentiating cardiogenic from noncardiogenic pulmonary edema:
9. Past Medical History
- Prior HF diagnosis (HFrEF vs. HFpEF), baseline LVEF
- Previous APE episodes, prior intubations
- Coronary artery disease, prior PCI/CABG
- Valvular disease (prosthetic valves, known stenosis/regurgitation)
- Hypertension, diabetes, CKD/ESRD, COPD
- Obstructive sleep apnea
- Thyroid disease (hyper- or hypothyroidism can precipitate HF) [6]
10. Physical Exam
Vital signs
- Hypertension (SBP often >180 mmHg in SCAPE) vs. hypotension (cardiogenic shock) [3][7]
- Tachycardia, tachypnea (RR >30), hypoxemia
Key findings
- Lung: Bilateral crackles/rales (may extend to apices in severe cases), wheezing ("cardiac asthma"), frothy sputum
- Cardiac: S3 gallop (specific for elevated LVEDP, 90–97% specificity), S4, murmurs (new MR, AS), displaced PMI [2]
- JVP: Elevated (most sensitive sign of congestion) [5]
- Extremities: Peripheral edema, cool/mottled extremities (low output), capillary refill
- Abdomen: Hepatomegaly, hepatojugular reflux, ascites
11. Lab Studies
- BNP / NT-proBNP: BNP <100 pg/mL makes HF unlikely; NT-proBNP <300 pg/mL has high negative predictive value [2][16]
- Troponin: Elevated in ACS-triggered APE; also mildly elevated from myocardial stress (type 2 MI) [5]
- BMP: Creatinine (renal function, diuretic dosing), electrolytes (hyponatremia = poor prognosis, K⁺ for diuretic safety) [5]
- CBC: Anemia as precipitant, leukocytosis (infection)
- Hepatic panel: Elevated transaminases suggest hepatic congestion or cardiogenic shock
- Lactate: Elevated in cardiogenic shock/hypoperfusion [7]
- ABG/VBG: Assess for hypoxemia, hypercapnia, acidosis (guides BiPAP vs. CPAP decision) [17]
- TSH: If new-onset HF or atrial fibrillation
- D-dimer: If PE is in the differential [14]
12. Imaging
Chest X-ray
- Cephalization of pulmonary vessels, Kerley B lines, peribronchial cuffing, bilateral alveolar infiltrates (bat-wing pattern), pleural effusions, cardiomegaly [18]
- Sensitivity ~81% for acute HF, but up to 20% of patients with acute HF have no CXR congestion [18]
Point-of-care ultrasound (POCUS)
- B-lines (≥3 per lung zone) — more accurate than CXR for pulmonary edema [16][19]
- Cardiac: LV function, RV dilation, pericardial effusion, valvular pathology
- IVC: Plethoric IVC suggests elevated RA pressure/volume overload; collapsible IVC may suggest SCAPE with fluid maldistribution [20]
Echocardiography
CT angiography: Only if PE is suspected
13. Special Tests
- Lung ultrasound: Rapid, bedside, superior to CXR for detecting pulmonary edema (ACEP Level C recommendation) [19]
- Ottawa Heart Failure Risk Score (OHFRS): Validated tool for ED disposition decision-making in acute HF [21-22]
- EHMRG30-ST: Risk stratification tool predicting 7- and 30-day mortality to guide admission vs. early discharge [22]
- Pulmonary artery catheterization: Reserved for diagnostic uncertainty or refractory shock; PCWP >18 mmHg confirms cardiogenic etiology [2]
14. ECG
Indications: Obtain on every patient with suspected APE — mandatory to rule out ACS and arrhythmia [2][23]
Key findings
- Atrial fibrillation — most important ECG finding in dyspneic patients (LR 3.8 for HF) [24]
- ST changes / T-wave abnormalities — may indicate ACS as trigger (LR 3.0 for new T-wave changes) [24]
- Left ventricular hypertrophy — suggests chronic hypertension
- Wide QRS / LBBB — associated with HFrEF, worse prognosis [23][25]
- Post-resolution: Diffuse deep T-wave inversions with QT prolongation can occur after nonischemic APE and resolve within ~1 week — do not mistake for ACS [26]
- Normal ECG: Decreases likelihood of HF (LR 0.64) but does not exclude it [24]
15. Assessment
Hemodynamic profiling is the critical first step — classify as warm/cold and wet/dry: [4][6]
- Warm and wet (most common): Congested but adequate perfusion → vasodilators + diuretics
- Cold and wet: Congested with hypoperfusion → inotropes ± vasopressors, consider mechanical support
- Cold and dry: Hypoperfused without congestion → cautious fluid challenge, inotropes
Severity spectrum
- Mild decompensation (gradual weight gain, worsening dyspnea) → IV diuretics [27]
- SCAPE (sudden onset, hypertensive, severe respiratory distress) → NIPPV + high-dose nitroglycerin [3]
- Cardiogenic shock (hypotension, end-organ hypoperfusion) → inotropes, vasopressors, mechanical circulatory support [7]
Complications: Respiratory failure requiring intubation, cardiogenic shock, arrhythmia, acute kidney injury, multiorgan failure
16. Treatment Plan
Immediate stabilization (simultaneous)
- Positioning: Sit patient upright (reduces preload, improves respiratory mechanics)
- NIPPV: Start BiPAP (IPAP 10–15, EPAP 5–10 cmH₂O) or CPAP (5–10 cmH₂O). BiPAP preferred if hypercapnic or acidotic. Expect improvement within ~60 minutes; if not, prepare for intubation [11][17]
- Nitroglycerin:
- SCAPE/hypertensive APE: High-dose IV bolus 400–2000 mcg, then infusion starting at 100–200 mcg/min, titrate to SBP reduction [3][8-9]
- Standard APE: SL NTG 0.4 mg q5min while establishing IV access, then infusion 10–200 mcg/min
- IV furosemide: 20–40 mg IV (diuretic-naïve) or 1–2.5× home dose IV (chronic users) — give when true volume overload is present [6][10]
Refractory hypertension
- Add clevidipine (1–2 mg/hr, titrate) or nicardipine (5 mg/hr, titrate) [3][12-13]
- Enalaprilat 0.625–1.25 mg IV if normal renal function [3]
Cardiogenic shock (SBP <90)
- Norepinephrine (first-line vasopressor) ± dobutamine (inotrope) [27-28]
- Avoid fluid boluses >250–500 mL [27]
- Early cardiology/critical care consultation for mechanical circulatory support (IABP, Impella, ECMO)
Intubation considerations
- Use ketamine or etomidate for induction (hemodynamically favorable)
- Avoid propofol in hypotensive patients
- Continue PEEP post-intubation to prevent hemodynamic collapse [29]
Treat the underlying cause: ACS → cath lab; arrhythmia → rate/rhythm control; infection → antibiotics; valvular emergency → surgical consultation
17. Disposition
ICU admission criteria: [5][21]
- Requiring continuous vasoactive infusions
- Ongoing NIPPV or mechanical ventilation
- Cardiogenic shock or hemodynamic instability
- Treatment-resistant respiratory failure
Telemetry/step-down admission
- New-onset HF requiring workup [5]
- Persistent congestion requiring IV diuretics
- Elevated troponin, new arrhythmia
- Renal dysfunction, hyponatremia, liver dysfunction [5]
Observation unit / early discharge may be considered if: [5][22]
- Known HF with clear correctable trigger (e.g., missed diuretic dose)
- Brisk response to initial IV diuretic with symptom relief
- Normal vital signs, normal renal/hepatic function
- Normal BNP and troponin
- Reliable outpatient follow-up within 7 days
Risk stratification tools such as the Ottawa HF Risk Score and EHMRG30-ST can assist disposition decisions. [21-22]
18. Follow Up / Return Precautions
Follow-up timing
- Cardiology or HF clinic within 7 days of discharge [22]
- PCP within 1–2 weeks
- Repeat labs (BMP, BNP) at follow-up to assess trajectory
Return precautions — instruct patients to return immediately for:
- Worsening shortness of breath, inability to lie flat
- Weight gain >2 lbs/day or >5 lbs/week
- Chest pain, palpitations, syncope
- Decreased urine output
- Confusion or lightheadedness
Patient counseling
- Daily weight monitoring (same scale, same time)
- Medication adherence (especially diuretics and antihypertensives)
- Sodium and fluid restriction
- Avoid NSAIDs and other sodium-retaining medications
- Expected recovery: Symptoms should improve within 24–72 hours with appropriate therapy; persistent symptoms warrant re-evaluation
References
1. Non-Invasive Positive Pressure Ventilation (CPAP or Bilevel NPPV) for Cardiogenic Pulmonary Oedema. — Berbenetz N, Wang Y, Brown J, et al. The Cochrane Database of Systematic Reviews. 2019.
2. Acute Pulmonary Edema. — Ware LB, Matthay MA. The New England Journal of Medicine. 2005.
3. Emergency Medicine Updates: Sympathetic Crashing Acute Pulmonary Edema. — Long B, Brady WJ, Gottlieb M. The American Journal of Emergency Medicine. 2025.
4. Acute Decompensated Heart Failure. — Daniel B. Sims,, Tuvia Ben Gal,, Binyamin Ben Avraham, Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease. 2023.
5. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. — Hollenberg SM, Warner Stevenson L, Ahmad T, et al. Journal of the American College of Cardiology. 2019.
6. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Heidenreich PA, Bozkurt B, Aguilar D, et al. Journal of the American College of Cardiology. 2022.
7. Cardiogenic Shock After Acute Myocardial Infarction: A Review. — Samsky MD, Morrow DA, Proudfoot AG, et al. The Journal of the American Medical Association. 2021.
8. High-Dose Nitroglycerin Infusion Description of Safety and Efficacy in Sympathetic Crashing Acute Pulmonary Edema: The HI-DOSE SCAPE Study. — Houseman BS, Martinelli AN, Oliver WD, Devabhakthuni S, Mattu A. The American Journal of Emergency Medicine. 2023.
9. Low-Dose Versus High-Dose Intravenous Nitroglycerin in the Treatment of Sympathetic Crashing Acute Pulmonary Oedema: A Systematic Review and Meta-Analysis Focusing on Efficacy, Safety and Outcomes. — Pramudyo M, Kamarullah W, Pranata R, et al. BMJ Open. 2025.
10. Evaluation and Management of the Child With Acute Decompensated Heart Failure: A Scientific Statement From the American Heart Association. — Cabrera AG, Price JF, Hong BJ, et al. Circulation. 2026.
11. Noninvasive Respiratory Support for Adults with Acute Respiratory Failure. — Munshi L, Mancebo J, Brochard LJ. The New England Journal of Medicine. 2022.
12. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, et al. Journal of the American College of Cardiology. 2025.
13. Nicardipine: When High Dose Nitrates Fail in Treating Heart Failure. — Raggi JR, O'Connell TW, Singer DJ. The American Journal of Emergency Medicine. 2021.
14. Predictive Value of Clinical and Laboratory Parameters in Differentiating Hypertensive Pulmonary Edema and Acute Pulmonary Embolism. — Kavvasoglu B, Kavvasoglu GH. European Review for Medical and Pharmacological Sciences. 2023.
15. Decision Support Tool for Early Differential Diagnosis of Acute Lung Injury and Cardiogenic Pulmonary Edema in Medical Critically Ill Patients. — Schmickl CN, Shahjehan K, Li G, et al. Chest. 2012.
16. Diagnosis of Acute Heart Failure in the Emergency Department: An Evidence-Based Review. — Long B, Koyfman A, Gottlieb M. The Western Journal of Emergency Medicine. 2019.
17. Positive Pressure Ventilation in the Cardiac Intensive Care Unit. — Alviar CL, Miller PE, McAreavey D, et al. Journal of the American College of Cardiology. 2018.
18. Heart Failure With Reduced Ejection Fraction: A Review. — Murphy SP, Ibrahim NE, Januzzi JL. The Journal of the American Medical Association. 2020.
19. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Heart Failure Syndromes: Approved by ACEP Board of Directors, June 23, 2022. — Annals of Emergency Medicine. 2022.
20. Taming the Tiger: Ultra High Dose Nitroglycerin in Managing Sympathetic Crashing Acute Pulmonary Edema Patient. — Siddiqua N, Bhaskararayuni J, Sahu AK, Kumar A, Nayer J. The American Journal of Emergency Medicine. 2023.
21. Disposition of Acute Decompensated Heart Failure From the Emergency Department: An Evidence-Based Review. — Rider I, Sorensen M, Brady WJ, et al. The American Journal of Emergency Medicine. 2021.
22. Trial of an Intervention to Improve Acute Heart Failure Outcomes. — Lee DS, Straus SE, Farkouh ME, et al. The New England Journal of Medicine. 2023.
23. Insights Into the Importance of the Electrocardiogram in Patients With Acute Heart Failure. — Gouda P, Brown P, Rowe BH, McAlister FA, Ezekowitz JA. European Journal of Heart Failure. 2016.
24. Does This Dyspneic Patient in the Emergency Department Have Congestive Heart Failure?. — Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. The Journal of the American Medical Association. 2005.
25. Integrative Review of Electrocardiographic Characteristics in Patients With Reduced, Mildly Reduced, and Preserved Heart Failure. — Pokhrel Bhattarai S, Block RC, Xue Y, et al. Heart & Lung : The Journal of Critical Care. 2023.
26. Large T Wave Inversion and QT Prolongation Associated With Pulmonary Edema: A Report of Nine Cases. — Littmann L. Journal of the American College of Cardiology. 1999.
27. Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature. — Long B, Koyfman A, Gottlieb M. The Journal of Emergency Medicine. 2018.
28. ACC/AHA Versus ESC Guidelines On Heart Failure: JACC Guideline Comparison. — van der Meer P, Gaggin HK, Dec GW. Journal of the American College of Cardiology. 2019.
29. Prevention of Complications in the Cardiac Intensive Care Unit: A Scientific Statement From the American Heart Association. — Fordyce CB, Katz JN, Alviar CL, et al. Circulation. 2020.